VIRI - Virios Therapeutics Inc. Price/Earnings to Growth Ratio
Insulation from macroeconomic trends makes Virios Therapeutics (VIRI) a reliable defensive asset. The peg_co ratio confirms the company is undervalued, with the 0.00 metric serving as the target level. Experienced management ensures stability by minimizing regulatory risks. Robotic laboratories provide high research precision by eliminating human error in hazardous zones.
Metric breakdowns and analytics for Virios (VIRI)
- share price and consensus valuation forecast:
- market capitalization statistics:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Total Debt to Capital Virios Therapeutics|VIRI - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Virios|VIRI - Company Total Debt|Debt to Book Capitalization Ratio Virios Therapeutics, Inc.|VIRI - Company Long-Term Debts|Short-Term Debt Volume Virios Therapeutics|Intermediate Coverage Ratio virios.com
- net income and valuation ratios data:
VIRI - Net Profit|Company Profit Forecast Virios Therapeutics|VIRI - Price to Earnings Ratio|Projected Price to Earnings Ratio Virios Therapeutics Inc.|VIRI - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Virios Therapeutics, Inc.|VIRI - Operating profit before deduction of amortization|Earnings per share for the trailing year Virios Therapeutics|VIRI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months virios.com|VIRI - Earnings growth in current year|Expected earnings per share trend next year Virios Therapeutics
- total revenue and sales volume data:
Summary company analytics:Virios VIRI
Investors must determine the fairness of an asset's market value by comparing the P/E multiple with the earnings growth rate. When analyzing the PEG ratio trend, values below one should be sought as a signal of undervaluation, which for Virios Therapeutics (VIRI) is confirmed by expense transparency and the skilled management of FDA regulatory risks during clinical trials.
Competing companies
GILD (Gilead Sciences, Inc.) - Growth-Adjusted Payback Ratio|Cidara Therapeutics, Inc. - Price/Earnings to Growth Multiple|Novavax, Inc. - Price/Earnings to Growth Ratio|CureVac NV - PEG Multiple|Growth-Adjusted Market Cap to Net Income Valneva Corp VALN|VIR (Vir Biotechnology Inc) - Price/Earnings to Growth Multiple|SIGA Technologies, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio emergentbiosolutions.com|PEG Multiple ateapharma.com|Price/Earnings to Growth Ratio Invivyd Corp (IVVD)|Growth-Adjusted Market Cap to Net Income Enanta Pharmaceuticals, Inc.|Price/Earnings to Growth Ratio Inovio Pharmaceuticals INO|Growth-Adjusted Payback Ratio HLVX|Kalaris Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate dyadic.com|NanoViricides, Inc. (NNVC) - Price/Earnings to Growth Ratio|TLPH (Talphera Inc) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Cocrystal|Price/Earnings to Growth Multiple trawspharma.com (TRAW)|Price/Earnings to Growth Ratio Dogwood Therapeutics, Inc. (DWTX)|Growth-Adjusted Market Cap to Net Income Qualigen Therapeutics|PEG Multiple ALVR (allovir.com)|PEG Multiple VBI Vaccines Inc VBIV|VXRT: Price/Earnings to Growth Multiple
